药明合联 - 2025 年亚太峰会反馈

November 20, 2025 09:10 AM GMT WuXi XDC Cayman Inc. | Asia Pacific M Update Asia Pacific Summit 2025 Feedback Questions centred on ramp-up for the Singapore site and margins impact: The Singapore site is expected to add an additional 8mn vials of drug products capacity in 2026, supporting commercial contracts for 2027-28 (note). XDC expects a few active contracts to be signed in the near term. The closest project to FDA inspection is Duality/BionTech's HER2 ADC. With the expansion in Wuxi city and Singapore ...